Tanabe Mitsubishi Holds Seminar on Withdrawing Remicade Treatment After Remission
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi held a seminar entitled, “Future Forecast of Rheumatoid Arthritis Treatment” 10 years after it received approval for Japan’s first biological agent, Remicade (infliximab).